Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neurotoxicity research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/10298420290007628PMID 12826493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tardive dyskinesia: pathophysiology and animal models.

  2000cited by this paper
• Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

  2000cited by this paper
• Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.

  1999cited by this paper
• Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells

  1999cited by this paper
• Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.

  1999cited by this paper
• Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.

  1999cited by this paper
• Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP.

  1998cited by this paper
• Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals.

  1998cited by this paper
• Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia.

  1998cited by this paper
• The Relationship Between Serum Concentration and Therapeutic Effect of Haloperidol in Patients with Acute Schizophrenia

  1998cited by this paper
• Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem.

  1997cited by this paper
• Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate?

  1997cited by this paper
• Studies on the metabolic bioactivation of haloperidol (HP) and its tetrahydropyridine dehydration product

  1996cited by this paper
• Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.

  1996cited by this paper
• Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1996cited by this paper
• Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon.

  1996cited by this paper
• Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol

  1996cited by this paper
• Drugs and the treatment of psychiatric disorders

  1996cited by this paper
• Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices

  1995cited by this paper
• Iron‐mediated bioactivation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in glial cultures

  1995cited by this paper
• Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxinN-methyl-4-phenylpyridinium (MMP+) towards cultured dopaminergic neuroblastoma cells

  1995cited by this paper
• Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.

  1995cited by this paper
• Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia

  1994cited by this paper
• Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.

  1994cited by this paper
• 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.

  1994cited by this paper
• MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.

  1994cited by this paper
• Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats.

  1993cited by this paper
• Chronic antagonist treatment does not alter the mode of interaction of dopamine with rat striatal dopamine receptors.

  1993cited by this paper
• Research and society: a relationship with two faces.

  1993cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection.

  1992cited by this paper
• Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.

  1991cited by this paper
• MPP+-LIKE NEUROTOXICITY OF HPP+, A PYRIDINIUM METABOLITE OF HALOPERIDOL - A MICRODIALYSIS STUDY

  1991cited by this paper
• Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.

  1991cited by this paper
• Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite.

  1991cited by this paper
• Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.

  1990cited by this paper
• Tardive dyskinesia

  1988cited by this paper
• Tardive dyskinesia

  1988cited by this paper
• In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology.

  1988cited by this paper
• Psychopharmacology: The Third Generation of Progress

  1988cited by this paper
• Radiolabelled clorgyline and l-deprenil: suicide inactivators of monoamine oxidase

  1987cited by this paper
• Preparation of the flavin-containing aromatic amine oxidases of human placenta and beef liver.

  1987cited by this paper
• Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1985cited by this paper
• Pargyline prevents MPTP-induced parkinsonism in primates.

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Tardive dyskinesia. A discontinuation study.

  1984cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Tardive dyskinesia: review and update.

  1980cited by this paper
• The pathophysiologic basis of tardive dyskinesia.

  1977cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• The preparation of microsomes

  1965cited by this paper
• Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice.

  1959cited by this paper

• Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism

  2022cites this paper
• Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side‐effects by different mechanisms

  2017cites this paper
• Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction.

  2016cites this paper
• P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry.

  2010cites this paper
• Electrochemical and Enzymatic In Vitro Studies on Reactive Drug Metabolites Synthesis, Characterization and Avoidance

  2010cites this paper
• Irreversible blockade of sigma‐1 receptors by haloperidol and its metabolites in guinea pig brain and SH‐SY5Y human neuroblastoma cells

  2007cites this paper
• Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain.

  2007cites this paper
• Drug-induced parkinsonism

  2006cites this paper
• Identification of a new functional target of haloperidol metabolite: implications for a receptor‐independent role of 3‐(4‐fluorobenzoyl) propionic acid

  2006cites this paper
• Drug-induced parkinsonism

  2006cites this paper